The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Mechanism of action of memantine
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Memantine is an uncompetitive NMDA receptor antagonist and prevents damage to AD patients caused by NMDA receptor overactivation.434”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [434]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate receptor ion channels
Mayer, M. L. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 3,640
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
Chen, H., Pellegrini, J., Aggarwal, S., Lei, S., Warach, S., Jensen, F., & Lipton, S. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-11-04427.1992 · Cited by 629
The Yin and Yang of NMDA receptor signalling
Hardingham, G. E., & Bading, H. (2003) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)00040-1 · Cited by 620
The Neuropharmacological Basis for the Use of Memantine in the Treatment of Alzheimer's Disease
Rogawski, M. A., & Wenk, G. L. (2003) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2003.tb00254.x · Cited by 436
Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404
Expression Mechanisms Underlying NMDA Receptor‐Dependent Long‐Term Potentiation
NICOLL, R. A., & MALENKA, R. C. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb11320.x · Cited by 365
Homeostatic plasticity and NMDA receptor trafficking
Pérez-Otaño, I., & Ehlers, M. D. (2005) · Trends in Neurosciences · doi:10.1016/j.tins.2005.03.004 · Cited by 356
Cited by
Lamptey, R. N. L., Chaulagain, B., Trivedi, R., Gothwal, A., Layek, B., & Singh, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031851 · Cited by 900
History and progress of hypotheses and clinical trials for Alzheimer’s disease
Liu, P.-P., Xie, Y., Meng, X.-Y., & Kang, J.-S. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0063-8 · Cited by 723
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 707
The chemical biology of clinically tolerated NMDA receptor antagonists
Chen, H. V., & Lipton, S. A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03991.x · Cited by 474
NMDA receptors in clinical neurology: excitatory times ahead
Kalia, L. V., Kalia, S. K., & Salter, M. W. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70165-0 · Cited by 415
Randomized Controlled Crossover Trial of Ketamine in Obsessive-Compulsive Disorder: Proof-of-Concept
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes, D., Flood, P., & Simpson, H. B. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.150 · Cited by 386
Structure, Function, and Pharmacology of NMDA Receptor Channels
VYKLICKY, V., KORINEK, M., SMEJKALOVA, T., BALIK, A., KRAUSOVA, B., KANIAKOVA, M., LICHNEROVA, K., CERNY, J., KRUSEK, J., DITTERT, I., et al. (2014) · Physiological Research · doi:10.33549/physiolres.932678 · Cited by 321
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Advances in developing novel therapeutic strategies for Alzheimer’s disease
Cao, J., Hou, J., Ping, J., & Cai, D. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0299-8 · Cited by 285
Sani, G., Serra, G., Kotzalidis, G. D., Romano, S., Tamorri, S. M., Manfredi, G., Caloro, M., Telesforo, C. L., Caltagirone, S. S., Panaccione, I., et al. (2012) · CNS Drugs · doi:10.2165/11634390-000000000-00000 · Cited by 273
Mg2+Imparts NMDA Receptor Subtype Selectivity to the Alzheimer's Drug Memantine
Kotermanski, S. E., & Johnson, J. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3703-08.2009 · Cited by 271
Self-citationReviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review
Minati, L., Edginton, T., Grazia Bruzzone, M., & Giaccone, G. (2009) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317508328602 · Cited by 268
Therapeutics of Neurotransmitters in Alzheimer’s Disease
Kandimalla, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-161118 · Cited by 268
Ketamine: NMDA Receptors and Beyond
Zorumski, C. F., Izumi, Y., & Mennerick, S. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1547-16.2016 · Cited by 254
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232
Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block
Dravid, S. M., Erreger, K., Yuan, H., Nicholson, K., Le, P., Lyuboslavsky, P., Almonte, A., Murray, E., Mosley, C., Barber, J., et al. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2006.124958 · Cited by 184
Tricco, A. C., Ashoor, H. M., Soobiah, C., Rios, P., Veroniki, A. A., Hamid, J. S., Ivory, J. D., Khan, P. A., Yazdi, F., Ghassemi, M., et al. (2018) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15069 · Cited by 137
Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
Varadharajan, A., Davis, A. D., Ghosh, A., Jagtap, T., Xavier, A., Menon, A. J., Roy, D., Gandhi, S., & Gregor, T. (2023) · Journal of Neurosciences in Rural Practice · doi:10.25259/jnrp_356_2023 · Cited by 123
Current and Emerging Pharmacotherapy for Fibromyalgia
Tzadok, R., & Ablin, J. N. (2020) · Pain Research and Management · doi:10.1155/2020/6541798 · Cited by 122
“Memantine, another receptor antagonist, was suggested to be useful because of its ability to reduce neurotoxicity caused by high levels of glutamate found in different brain areas of FMS patients [31, 32].”
BackgroundCalcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures
Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91
Shin, M., Liu, Q. F., Choi, B., Shin, C., Lee, B., Yuan, C., Song, Y. J., Yun, H. S., Lee, I.-S., Koo, B.-S., et al. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00495 · Cited by 80
Li, Y., Sang, S., Ren, W., Pei, Y., Bian, Y., Chen, Y., & Sun, H. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113874 · Cited by 77
de Bartolomeis, A., Sarappa, C., Buonaguro, E. F., Marmo, F., Eramo, A., Tomasetti, C., & Iasevoli, F. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.06.010 · Cited by 72
Cognition as a target in major depression: new developments.
Solé, B., Jiménez, E., Martinez-Aran, A., & Vieta, E. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.12.004 · Cited by 68
Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.10l06653 · Cited by 59
Kaur, B., & Prakash, A. (2017) · Pathophysiology · doi:10.1016/j.pathophys.2017.02.001 · Cited by 54
Amidfar, M., Réus, G. Z., Quevedo, J., & Kim, Y.-K. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.03.023 · Cited by 43
Muolokwu, C. E., Chaulagain, B., Gothwal, A., Mahanta, A. K., Tagoe, B., Lamsal, B., & Singh, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1405423 · Cited by 42
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Nirogi, R., Ieni, J., Goyal, V. K., Ravula, J., Jetta, S., Shinde, A., Jayarajan, P., Benade, V., Palacharla, V. R. C., Dogiparti, D. K., et al. (2022) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12307 · Cited by 29
Pringle, A., Parsons, E., Cowen, L., McTavish, S., Cowen, P., & Harmer, C. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112446535 · Cited by 21
Haller, O. J., Semendric, I., George, R. P., Collins-Praino, L. E., & Whittaker, A. L. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105120 · Cited by 13
“Memantine (n = 2) is an antagonist of the NMDA subclass of glutamate receptors that blocks current flow through channels of these receptors and is often used to treat AD (Johnson and Kotermanski, 2006).”
BackgroundPolymers for the treatment of Alzheimer’s disease
Zhu, Y., Xu, H., Yu, C., Jiang, W., Hou, X., Ma, M., & Wu, J. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1512941 · Cited by 5
“Memantine (MEM) is an NMDA receptor inhibitor approved for AD treatment, NMDAR is present on the postsynaptic membrane and its hyperactivation leading to a large inward fl ow of Ca 2+ is considered one of the main causes of synaptic failure in AD patients (Johnson and Kotermanski, 2006).”
Auvelity as a Potential Treatment for Alzheimer’s Disease
Lepkowsky, C. M. (2022) · Medical Research Archives · doi:10.18103/mra.v10i10.3206 · Cited by 2
Metadata
- Authors
- JOHNSON, J., & KOTERMANSKI, S.
- Venue
- Current Opinion in Pharmacology
- Publisher
- Elsevier BV
- Published
- 2006-02
- Volume
- 6
- Issue
- 1
- Pages
- 61-67
- ISSN
- 1471-4892 (ISSN-L)
- OpenAlex
- W2009297217
- Cited by
- 502
- References
- 57
- FWCI
- 2.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.